Acquired resistance to conventional melanoma therapies (either targeted- or immuno- therapy) caused by various bypass signaling activation mechanisms, leads to limited efficacy of currently available BRAF inhibitors, vemurafenib and PLX8394. Here, BRAF is linked to melanoma.